Jump to main content.

Oryzalin Quickview (CASRN 19044-88-3)

Health assessment information on a chemical substance is included in IRIS only after a comprehensive review of toxicity data by U.S. EPA health scientists from several Program Offices, Regional Offices, and the Office of Research and Development.

Disclaimer: This QuickView represents a snapshot of key information. We suggest that you read the IRIS Summary to put this information into complete context.

For definitions of terms in the IRIS Web site, refer to the IRIS Glossary.

Status of Data for Oryzalin

File First On-Line: 01/31/1987; Last Significant Revision: 07/01/1989

Category (section)
Last Revised
Oral RfD Assessment Yes 07/01/1989
Inhalation RfC Assessment No
Carcinogenicity Assessment Yes 08/22/1988
  • 19044-88-3
  • 4-(Dipropylamino)-3,5-dinitrobenzenesulfonamide
  • dirimal
  • EL-119
  • Oryzalin
  • Rycelan
  • Rycelon
  • Ryzelan
  • Sulfanilamide, 3,5-dinitro-n(sup 4),n(sup 4)-dipropyl-
  • Surflan
  • 3,5-dinitro-n(sup 4),n(sup 4)-dipropylsulfanilamide
Oryzalin Source Documents
Chronic Health Hazard Assessments for Noncarcinogenic Effects

Reference Dose for Chronic Oral Exposure (RfD)

Critical Effect
Point of Departure*
Increases in serum cholesterol, alkaline phosphatase, and relative liver and kidney weights, and decreases in alanine transaminase and adrenal weights NOEL : 5 mg/kg-day 100 5 x10-2 mg/kg-day

* The Point of Departure listed serves as a basis from which the Oral RfD was derived. See Discussion of Conversion Factors and Assumptions for more details.

Top of page

Reference Concentration for Chronic Inhalation Exposure (RfC)

Not Assessed under the IRIS Program.

Top of page

Carcinogenicity Assessment for Lifetime Exposure
  • Weight-of-Evidence Characterization
    • C (Possible human carcinogen)
  • Weight-of-Evidence Narrative:
    • Oryzalin produced tumors (generally benign) at multiple sites in male and female rats. It is structurally related to 2,4-diaminoanisole sulfate which causes malignant tumors at similar sites.
    • This may be a synopsis of the full weight-of-evidence narrative. See IRIS Summary.

Quantitative Estimate of Carcinogenic Risk from Oral Exposure

  • Not Assessed under the IRIS Program.

Quantitative Estimate of Carcinogenic Risk from Inhalation Exposure

  • Not Assessed under the IRIS Program.

Top of page

Recent Additions | Advanced Search | IRIS Home | Environmental Assessment | Research

Local Navigation

Jump to main content.